Pharmaceutical manufacturers of Minocycline

Founded in 1956, Zhejiang Hisun Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise featuring whole chain, multi-regional integration of research, production and marketing as well as development of drug substances and preparations. In 2000, an A-share was issued in order to enter the stock market as a state-owned listed company. As of 2021, Hisun Pharmaceutical is now one of the largest producers of antibiotics and anti-tumor drugs in China and has been listed in the Top 500 Chinese manufacturing enterprises and the Top 100 Chinese pharmaceutical enterprises multiple times. In 2020 Hisun Pharmaceuticals received special recognition from the Joint Prevention and Control Team from the State Council of the People’s Republic of China for their extraordinary efforts in the fight against the epidemic, and Hisun Pharmaceutical was awarded with the “Anti COVID-19 Advanced Collective in Ministry of Industry and Information Technology".

Bringing 86 years of expertise, UQUIFA'S operational approach is built on a fusion of a high-quality production platform and a proven history of service and dependability. UQUIFA specializes in the production of Active Pharmaceutical Ingredients (APIs), Intermediates, and RSM's for the pharmaceutical and animal health sectors on a global scale. The organization runs 2 production facilities (located in Spain and Mexico) with stringent compliance to all regulatory standards. These facilities operate under cGMP conditions and have undergone evaluation and endorsement from prominent global pharmaceutical companies.

We are utilizing the world's top-level fermentation and synthesis technologies to supply domestic and overseas users with various fine chemical products centered on amino and nucleic acids for pharmaceuticals, nutritional supplements, and industrial use, as well as the derivatives of such acids. Through the rapid progress in genome analysis seen in recent years, we anticipate the development of new biotechnology processes and products from fermentation, a technology which humankind has been utilizing since time immemorial.

Nuray Chemicals Pvt Ltd is a manufacturing facility approved by the US Food and Drug Administration (USFDA) for active pharmaceutical ingredients (API) with an advanced research and development/manufacturing site situated in Thiruvallur, near Chennai, in the state of Tamil Nadu, India. Nuray has extensive experience in launching products in the pharmaceutical industry, particularly in developing niche, novel, and challenging-to-produce APIs for commercial use, meeting chemistry requirements through synthesis.

Hovione brings over six decades of experience as a CDMO and serves as a specialized integrated provider delivering solutions for drug substance, drug product intermediate, and drug product. With four FDA examined facilities in the United States, China, Ireland, and Portugal, as well as research laboratories in Portugal and the United States, the company supplies pharmaceutical customers with services for the development and compliant production of innovative drugs, including highly potent compounds. Hovione delivers a comprehensive range of development services and manufacturing capabilities in particle engineering such as Spray Drying.

Established in 1993, SUANFARMA is a business-to-business partner in the field of life sciences specializing in the formulation, manufacture, and marketing of components for the pharmaceutical, veterinary, and nutraceutical sectors. In SUANFARMA, we provide our CDMO capabilities for fermentation and chemical synthesis projects, delivering a comprehensive service with a proven track record, facilitating success in the formulation, expansion, production, and marketing of an API, whether it is innovative or generic

Zhejiang Huida Biotech Co., Ltd. is situated in Hangzhou, within Zhejiang Province. It was founded in 2020 and operates as a subsidiary of Huadong Medicine Co., Ltd. The organization specializes in the exploration and formulation of microbial active pharmaceutical substances (APIs), intermediates, and extensive health products. It stands as a technologically inventive research enterprise in the field of fermentation products. Leveraging robust R&D capabilities, the corporation delivers top-notch technology, service, and products to its global clientele by uncovering and nurturing the most valuable microbial metabolites.

Zhejiang Medicine currently has nine major subsidiaries, including Xinchang Pharmaceutical Factory, Vitamin Factory, Changhai Biological Company, Zhejiang Health Creation Biotechnology Co., Ltd., Zhejiang LaiYi Medicine Co., Ltd., Zhejiang Novus Pharmaceuticals Co., Ltd., Zhejiang Changhai Pharmaceuticals Co., Ltd., Shanghai Vital Health Management Co., Ltd., NovoCodex Biopharmaceuticals. Co., Ltd., and two research units, the Pharmaceutical Industry Research Institute and the Shanghai Laiyi Biopharmaceutical R&D Center. The company has more than 6,800 employees, including more than 2,500 professional and technical personnel, who account for more than 37% of the company’s total number of employees.